首页 | 本学科首页   官方微博 | 高级检索  
检索        

右美托咪定对舌癌患者围术期免疫功能的影响
引用本文:汤耀平,林丽玲,刘付宁,刘玲,曹铭辉.右美托咪定对舌癌患者围术期免疫功能的影响[J].岭南急诊医学杂志,2012,17(2):115-117.
作者姓名:汤耀平  林丽玲  刘付宁  刘玲  曹铭辉
作者单位:中山大学孙逸仙纪念医院麻醉科,510120
摘    要:目的:探讨右美托咪定(Dex)对舌癌患者围术期免疫功能的影响.方法:将ASAⅠ~Ⅱ级拟行舌癌根治全麻择期手术患者30例随机分为右美托咪定组(Dex组)和对照组各15例.全麻诱导前,Dex组持续泵入右美托咪定0.5 μg/kg(溶于10 mL生理盐水),对照组静脉持续泵人生理盐水10 mL,均在10 min内完成.以相同药物快速诱导插管,插管后Dex组以Dex、七氟醚、瑞芬太尼维持;对照组以七氟醚、瑞芬太尼维持.分别于TO(诱导前)、T1(切皮前,诱导后20 min)、T2(切皮后,诱导后50min)测定CD3+、CD4+、CD8+、CD4+/CD8+及NK细胞比例.结果:两组在TO时间点CD3+、CD4+、CD8+、CD4+/CD8+以及NK细胞的分布差异无统计学意义(P>0.05).Dex组各个时间点CD3+、CD4+、CD8+、CD4+/CD8+及NK细胞变化不明显.相对于TO时间点,对照组T1、T2时间点CD3+、CD4+、C D4+/CD8+和NK细胞呈下降趋势,而CD8+升高.和对照组比较,Dex组在T1、T2时闻点CD4+/CD8+、NK细胞升高,而CD8+降低.结论:Dex作为麻醉辅助药物能减轻全麻药物对舌癌患者免疫功能的影响.

关 键 词:右美托咪定  舌癌患者  免疫功能

Effect of Dexmedetomidine on the Immunological Status of Patients with Tongue Carcinoma
TANG Yao-ping , LIN Li-ling , LIU Fu-ning , LIU Ling , CAO Ming-hui.Effect of Dexmedetomidine on the Immunological Status of Patients with Tongue Carcinoma[J].Lingnan Journal of Emergency Medicine,2012,17(2):115-117.
Authors:TANG Yao-ping  LIN Li-ling  LIU Fu-ning  LIU Ling  CAO Ming-hui
Institution:(Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou ,510120, China)
Abstract:Objective: To explore the effect of Dexmedetomidine (Dex) on the immunological status of patients with tongue carcinoma. Methods:30 patients with tongue carcinoma underwent surgery with general anesthesia (ASA Ⅰ~Ⅱ ) were included. Patiems were randomly divided into Dex group and control group, each n=15. The patients in the Dex group received 0.5 μg/kg of Dex before induction. After rapid induction and intubation, the Dex group was received Dex, sevofluran and remifentanil for maintenance and the control group received sevofluran and remifentanil instead. The CD3+,CD4+,CD8+,CD4+/CD8+ and NK cell percentage were detected at 3 time points:T0 (before induction), T1 (before skin incision, 20 rain after induction), T2 (after skin incision, 50 rain after induction). Results: The CD3+, CD4+, CD8+, CD4+/CD8+ and NK cells distribution had no significant differences at TO between the two groups (P〉0.05). The CD3+, CD4+, NK cells percentage and CD4+/CD8+ decreased at T1,T2 when compared with TO in the control group, whereas CD8+were increased. The CD3+, CD4+, CD8+, CD4+/CD8+ and NK cells did not change significantly in Dex group at each time point. The CD4+/CD8+ and NK cells percentage in Dex group at T1, T2 were higher than those in the control group. Conclusion: Dex as an anesthetic adjuvant, can decrease the suppression of immune status by general anesthetics in patients with tongue carcinoma.
Keywords:Dexmedetomidine  tongue carcinoma  immune function
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号